The primary investment objective of the scheme is to seek to generate consistent returns bypredominantly investing in equity and equity related securities of pharmaceutical and healthcarecompanies.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 2.2% | 17.47% | 19.58% | 13.29% | N/A | 20.34% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 4.46% | 62.16% | 104.59% | 86.68% | N/A | 330.9% |
| Rank within category | 2/19 | 4/18 | 6/18 | 10/18 | 8/17 | 10/14 | 7/12 | 4/10 | 4/9 | N/A | N/A |
| Sector Funds | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|---|
| Yearly returns | N/A | 7.69% | 76.9% | 23.3% | -7.79% | 35% | 40.69% | -5.81% | 9.91% |
| Q1 returns | N/A | 2.99% | -0.76% | -0.61% | -7.96% | -4.59% | 10.74% | -10.15% | -7.8% |
| Q2 returns | N/A | -6.02% | 26.17% | 13.2% | -11.9% | 14.7% | 1.88% | 4.31% | 19.21% |
| Q3 returns | N/A | 1.07% | 28.85% | 7.5% | 9.13% | 9.6% | 22.29% | -1.3% | 3.48% |
| Q4 returns | N/A | 10.07% | 9.65% | 1.95% | 4.21% | 12.55% | 1.97% | 1.83% | -3.37% |
0.50% on or before 1M, Nil after 1M
| Alpha | 1.11716 |
| Beta | 0.5825 |
| Sharpe Ratio | 0.288051 |
| Sortino Ratio | 0.63554 |
| R-Squared | 0.2778 |
| Tracking Error | 3.6975 |
| Downside Risk | 15.9512 |
| Std. Deviation (Annualised) | 13.7751 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth Current | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Tata India Pharma & Healthcare Fund - Regular Plan - Growth | -7.42% | -6.38% | 5.15% | 4.71% | -0.23% | 15.22% | 11.84% | 12.5% | 11% | 1,511.49 | 2.37 | 0.23 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.13% |
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.44% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.18% |
| TREPS / Reverse Repo Investments | Cash & Cash Equivalents and Net Assets | 6.81% | |
| Sai Life Sciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.52% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.15% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 6.07% |
| Globus Medical Inc | Healthcare Equipment & Supplies | Overseas Equities | 5.15% |
| Alkem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.75% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 4.17% |
| Cohance Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.79% |
| Alembic Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.18% |
| Kovai Medical Center & Hospital Ltd. | Healthcare Services | Domestic Equities | 2.83% |
| Pfizer Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.72% |
| Concord Biotech Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.70% |
| Procter & Gamble Health Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.36% |
| Vijaya Diagnostic Centre Ltd. | Healthcare Services | Domestic Equities | 2.36% |
| Indoco Remedies Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.26% |
| Intuitive Surgical Inc | Healthcare Equipment & Supplies | Overseas Equities | 1.95% |
| Thyrocare Technologies Ltd. | Healthcare Services | Domestic Equities | 1.91% |
| Manipal Health Enterprises Ltd. | Healthcare Services | Domestic Equities | 1.85% |
| Unichem Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.64% |
| Syngene International Ltd. | Healthcare Services | Domestic Equities | 1.35% |
| Nephrocare Health Services Ltd. | Healthcare Services | Domestic Equities | 1.12% |
| Global X Funds - Global X Genomics & Biotechnology ETF | Foreign Security | Overseas Mutual Fund Units | 1.10% |
| ICICI Lombard General Insurance Company Ltd. | Insurance | Domestic Equities | 1.02% |
| Aarti Drugs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.98% |
| Abbott Laboratories | Pharmaceuticals & Biotechnology | Overseas Equities | 0.80% |
| Eris Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.72% |
| Jupiter Life Line Hospitals Ltd. | Healthcare Services | Domestic Equities | 0.35% |
| Grail Inc | Healthcare Equipment & Supplies | Overseas Equities | 0.31% |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.26% |
| Laxmi Dental Ltd. | Healthcare Equipment & Supplies | Domestic Equities | 0.14% |
| Net Receivables/Payables | Cash & Cash Equivalents and Net Assets | -0.09% | |
| Total | 100.00% | ||
Chirag has a total work experience of over 20 years. He joined DSP Mutual Fund in November 2020 as Vice President in the Equity Team. Chirag has also worked with HDFC AMC Limited, Aviva Life Insurance, ICICI Securities, Infinity.com Financial Services Ltd., Global Markets - Deutsche Equities India Pvt. Ltd., Citigroup Global Markets India Pvt. Ltd., and ICICI Securities. He is a C.A. (ICAI India) and also holds a B.Com degree.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
